Article
M&A Deal Values Soar in Q1 2024
IQVIA Pharma Deals
Jun 19, 2024

After a flurry of merger and acquisition (M&A) deals were announced by life science companies at the end of 2023, there was the expectation that momentum would be sustained through Q1 2024. However, continued macroeconomic pressures and regulatory uncertainties led to a slight decline in number of M&A deals in Q1 2024, with only 84 deals signed compared to 93 in Q1 2023. Despite this, deal values were up significantly compared to the same period last year, as companies were willing to commit large sums of cash to acquire companies with established, de-risked assets that complemented their existing portfolios. Q1 2024 also saw the return of big pharma companies to the M&A dealmaking table, with 15% of these transactions announced involving a top 20 ranked pharma company.

Download the full article to unlock insights on how big pharma fueled M&A deal values and gain an outlook.

Related solutions

Contact Us